Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer

Samantha Torquato, PhD1; Aparna Pallavajjala, MS2; Alexa Goldstein, MS1; Patricia Valda Toro, MS1; John L. Silverstein, MS1; Justin Lee1; Mary Nakazawa, MS1; Ian Waters1; David Chu, PhD1; Daniel Shinn1; Taylor Groginski1; Robert M. Hughes, PhD1; Brian W. Simons, DVM, PhD1; Hamda Khan, MS1; Zhaoyong Feng, MS1; Michael A. Carducci, MD, FACP1; Channing J. Paller, MD1; Samuel R. Denmeade, MD1; Bruce Kressel, MD1; Mario A. Eisenberger, MD1; Emmanuel S. Antonarakis, MBBCh1; Bruce J. Trock, PhD1; Ben H. Park, MD, PhD1,2; and Paula J. Hurley, PhD1

PURPOSE Androgen receptor (AR) gene alterations, including ligand-binding domain mutations and copy number (CN) gain, have yet to be fully established as predictive markers of resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). The goal of this study was to validate AR gene alterations detected in cell-free DNA (cfDNA) as markers of enzalutamide and abiraterone resistance in patients with mCRPC.

METHODS Patients with mCRPC (N = 62) were prospectively enrolled between 2014 and 2018. Blood was collected before therapies—enzalutamide (n = 25), abiraterone (n = 35), or enzalutamide and abiraterone (n = 2)—and at disease progression. We used deep next-generation sequencing to analyze cfDNA for sequence variants and CN status in AR and 45 additional cancer-associated genes. Primary end points were prostate-specific antigen response, progression-free survival (PFS), and overall survival (OS).

RESULTS Elevated tumor-specific cfDNA (circulating tumor DNA) was associated with a worse prostate-specific antigen response (hazard ratio [HR], 3.17; 95% CI, 1.11 to 9.05; \(P = .031\)), PFS (HR, 1.76; 95% CI, 1.03 to 3.01; \(P = .039\)), and OS (HR, 2.92; 95% CI, 1.40 to 6.11; \(P = .004\)). AR ligand-binding domain missense mutations (HR, 2.51; 95% CI, 1.15 to 5.72; \(P = .020\)) were associated with a shorter PFS in multivariable models. AR CN gain was associated with a shorter PFS; however, significance was lost in multivariable modeling. Genetic alterations in tumor protein p53 (HR, 2.70; 95% CI, 1.27 to 5.72; \(P = .009\)) and phosphoinositide 3-kinase pathway defects (HR, 2.62; 95% CI, 1.12 to 6.10; \(P = .026\)) were associated with a worse OS in multivariable models.

CONCLUSION These findings support the conclusion that high circulating tumor DNA burden is associated with worse outcomes to enzalutamide and abiraterone in men with mCRPC. Tumor protein p53 loss and phosphoinositide 3-kinase pathway defects were associated with worse OS in men with mCRPC. AR status associations with outcomes were not robust, and additional validation is needed.

INTRODUCTION Next-generation therapies that target the androgen–androgen receptor (AR) axis, such as abiraterone and enzalutamide, have improved survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC), but both primary and acquired resistance to these drugs continue to be a substantial clinical challenge. Resistance mechanisms are not fully understood; however, some forms of resistance likely involve alterations to AR, including amplification and ligand-binding domain (LBD) missense mutations. Although rare in primary prostate cancers, AR gene alterations are highly prevalent in mCRPC. Metastatic tissue biopsies as a sole means to detect and observe changes in AR status is impractical, and thus cell-free DNA (cfDNA) is gaining traction as a minimally invasive and easily obtainable tumor biopsy surrogate. Previous studies using cfDNA from the blood to evaluate the association of AR gene aberrations with resistance to abiraterone and enzalutamide are inclusive. AR copy number (CN) gain and/or amplification or detection of two or more AR mutations have been associated with worse outcomes to such therapies as abiraterone and enzalutamide. In
contrast, a recent study demonstrated that neither AR CN gain, nor AR LBD mutations, were significantly associated with time to progression on abiraterone and enzalutamide therapies. Thus, the role of AR gene aberrations in mediating resistance to androgen–AR axis therapies has not been fully determined, and additional prospective studies are needed for clinical validation.

AR gene alterations are only detected in a subset of patients who have either primary or acquired resistance to androgen–AR therapies, thereby highlighting the need to determine other mechanisms that mediate resistance. The AR splice variant AR-V7 is associated with resistance to enzalutamide and abiraterone and is also associated with increased AR CN. In addition to AR, alterations in other genes, including tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN), and breast cancer gene 2 (BRCA2), are enriched in lethal prostate cancer. Studies support the idea that lineage plasticity from an AR-dependent to an AR-independent state through loss of TP53 and retinoblastoma-associated protein 1 (RB1) mediates resistance to AR-targeted therapies.

Consistent with this, TP53 defects have been shown to be associated with worse outcomes with abiraterone and enzalutamide therapies. The role of BRCA2 and other homology-directed repair (HDR) genes in mediating resistance to enzalutamide and abiraterone has not been definitively determined. Although it has been reported that truncating mutations in BRCA2 and ataxia-telangiectasia mutated (ATM) gene are associated with a shorter time to progression on enzalutamide and abiraterone, other studies have indicated that HDR defects may be associated with a better response to therapy.

The primary goal of this study was to determine whether AR CN gain and/or LBD mutations detected in cfDNA were associated with enzalutamide and abiraterone resistance in patients with mCRPC. The secondary goal was to determine if alterations in other genes that are enriched in lethal prostate cancer, including TP53, PTEN, and BRCA2, were associated with response to enzalutamide and abiraterone. In this study, high circulating tumor DNA (ctDNA) burden was significantly associated with prostate-specific antigen (PSA) response, progression-free survival (PFS), and overall survival (OS). AR LBD mutations were associated with a shorter PFS, whereas AR CN gain was associated with both a shorter PFS and worse OS, but lost significance in multivariable analyses. TP53 loss and defects in the phosphoinositide 3-kinase (PI3K) pathway were both associated with worse OS. Study limitations, including sample size and patient heterogeneity, necessitate larger and prospective validation of the association of plasma AR status with outcomes.

METHODS

Patient information, study end points, sample collection, deep next-generation sequencing (NGS), sequence alignment and analysis of variants, CN variation, estimation of ctDNA fraction, and statistical analyses are found in the Data Supplement.

RESULTS

Patient Cohort

Patient characteristics are listed in Table 1. PSA, PSA response, and PFS were not significantly different between patients on abiraterone and enzalutamide (Table 1 and Data Supplement). Approximately one quarter of patients had received prior abiraterone or enzalutamide. Prior abiraterone or enzalutamide exposure trended toward an association for worse outcomes, including PSA response (odds ratio [OR], 2.41; 95% CI, 0.74 to 7.93; P = .146), PFS (hazard ratio [HR], 1.17; 95% CI, 0.63 to 2.14; P = .620), and OS (HR, 1.51; 95% CI, 0.71 to 3.24; P = .284); however, these associations did not reach statistical significance (Tables 2 and 3 and Data Supplement). ClinVar-annotated pathogenic or likely pathogenic missense mutations, truncating mutations, and/or CN alterations were detected in cfDNA from 89% of patients before therapy initiation and in 92% of patients at disease progression (Figs 1A-1D and Data Supplement).

cDNA

Total cfDNA concentration before therapy was associated with PSA (P = .002; Data Supplement). We used deep NGS to analyze cfDNA for CN variation and mutations in 46 cancer-associated genes (Data Supplement). Nearly all patients (61 of 62) had detectable CN variation(s) and/or mutation(s) with an allelic frequency above the 1% cutoff before therapy (Figs 1B and 1C). High ctDNA was detected in approximately 44% of patients before therapy (Fig 1C). Consistent with previous findings, high ctDNA was significantly associated with a worse PSA response (OR, 3.17; 95% CI, 1.11 to 9.05; P = .031) by logistic regression analyses (Table 2). High ctDNA was associated with a significantly shorter median time to progression (14.0 weeks v 34.0 weeks; P = .022) and, using proportional hazards regression modeling, a shorter PFS (HR, 1.76; 95% CI, 1.03 to 3.01; P = .039; Table 3 and Fig 2A). High ctDNA was also significantly associated with a shorter median survival (62.7 weeks v 134.9 weeks; P = .003) and worse OS (HR, 2.92; 95% CI, 1.40 to 6.11; P = .004; Table 3 and Fig 3A). Other clinical variables, such as PSA, age, and visceral metastases, were not significantly associated with PSA response, PFS, or OS in univariable analyses (Tables 2 and 3 and Data Supplement).

AR

Previous studies that evaluated associations between AR gene alterations, including CN gain and LBD missense mutations, with therapeutic outcomes are not definitive. AR CN gain was detected in approximately one half of patients before therapy and at disease progression (Figs 1C and 1D and Data Supplement). AR CN gain was not
significantly associated with PSA response by logistic regression analysis (P = .119; Table 2 and Fig 2B), but was associated with a shorter median time to progression (16.1 weeks v 34.0 weeks; P = .013) and a shorter median survival (62.7 weeks v 144.9 weeks; P = .002; Figs 2C and 3B). Using proportional hazards regression modeling, PFS (HR, 2.07; 95% CI, 1.20 to 3.57; P = .009) and OS (HR, 3.26; 95% CI, 1.52 to 7.11; P = .002) were shorter in patients with AR CN gain; however, significance was lost upon inclusion of ctDNA burden in multivariable modeling (Figs 2C and 3B and Table 3).

Pathogenic AR LBD missense mutations were detected in cfDNA from 13% (eight of 62) of patients before therapy initiation and in an additional 15% (four of 26) of evaluable patients at disease progression (Figs 1C, 1D, and 2D and Data Supplement). Of the eight patients who had detectable AR LBD mutations before therapy, six did not have a PSA response, whereas two patients who harbored the

---

**TABLE 1. Patient Characteristics (N = 62)**

| Characteristic                              | Total Cohort (N = 62) | Abiraterone (n = 35) | Enzalutamide (n = 25) | Abiraterone Plus Enzalutamide (n = 2) |
|---------------------------------------------|----------------------|----------------------|-----------------------|---------------------------------------|
| **Age, years, median (range)**             | 71.5 (41-90)         | 71 (51-90)           | 73 (41-90)            | 79 (70-87)                            |
| **Race**                                   |                      |                      |                       |                                       |
| White                                      | 51 (82.3)            | 27 (77.1)            | 24 (96.0)             | 0 (0)                                 |
| Black                                      | 7 (11.3)             | 6 (17.1)             | 0 (0)                 | 1 (50)                                |
| Other                                      | 4 (6.5)              | 2 (5.7)              | 1 (4.0)               | 1 (50)                                |
| **Local treatment of prostate cancer**     |                      |                      |                       |                                       |
| Radical prostatectomy                       | 24 (38.7)            | 14 (40.0)            | 9 (36.0)              | 1 (50)                                |
| Radiation                                  | 9 (14.5)             | 3 (8.6)              | 5 (20.0)              | 1 (50)                                |
| Other                                      | 4 (6.5)              | 3 (8.6)              | 1 (4.0)               | 0 (0)                                 |
| None                                       | 24 (38.7)            | 14 (40.0)            | 10 (40.0)             | 0 (0)                                 |
| Not available                               | 1 (1.6)              | 1 (2.9)              | 0 (0)                 | 0 (0)                                 |
| **Gleason sum**                            |                      |                      |                       |                                       |
| ≤ 7                                        | 14 (22.6)            | 10 (28.6)            | 2 (8.0)               | 2 (100)                               |
| ≥ 8                                        | 42 (67.7)            | 22 (62.9)            | 20 (80.0)             | 0 (0)                                 |
| Not available                               | 6 (9.7)              | 3 (8.6)              | 3 (12.0)              | 0 (0)                                 |
| **Prior treatment of metastatic prostate cancer** |                      |                      |                       |                                       |
| Prior chemotherapy                         | 13 (21.0)            | 5 (14.3)             | 8 (32.0)              | 0 (0)                                 |
| Prior abiraterone                          | 10 (16.1)            | 2 (5.7)              | 8 (32.0)              | 0 (0)                                 |
| Prior enzalutamide                         | 5 (8.1)              | 4 (11.4)             | 1 (4.0)               | 0 (0)                                 |
| **Median PSA, ng/mL (range)**              | 19.3 (0.6-1966)      | 18.2 (0.6-1966)      | 18.9 (0.9-205.9)      | 102.6 (54.2-151.0)                    |
| **Site of metastases**                     |                      |                      |                       |                                       |
| Bone only                                  | 34 (54.8)            | 21 (60.0)            | 13 (52.0)             | 0 (0)                                 |
| Visceral only                              | 3 (4.8)              | 0 (0)                | 3 (12.0)              | 0 (0)                                 |
| Lymph node only                            | 4 (6.5)              | 1 (2.9)              | 3 (12.0)              | 0 (0)                                 |
| Bone and visceral                          | 3 (4.8)              | 1 (2.9)              | 1 (4.0)               | 1 (50)                                |
| Bone and lymph node                        | 18 (29.0)            | 12 (34.3)            | 5 (20.0)              | 1 (50)                                |
| **Study therapy**                          |                      |                      |                       |                                       |
| Abiraterone plus prednisone                | 35 (56.5)            | 35 (100)             | 0 (0)                 | 0 (0)                                 |
| Enzalutamide                               | 25 (40.3)            | 0 (0)                | 25 (100)              | 0 (0)                                 |
| Abiraterone plus prednisone and enzalutamide| 2 (3.2)              | 0 (0)                | 2 (100)               |                                       |
| **Median progression-free survival, weeks (range)** | 25.9 (2.3-162.7)     | 26.1 (3.7-162.7)     | 24.7 (2.3-103.4)      | 7.9 (4.6-11.1)                        |
| Prostate cancer–specific mortality         | 30 (48.4)            | 11 (31.4)            | 17 (68.0)             | 2 (100)                               |
| **Median follow-up, weeks (range)**        | 74.0 (4.7-182.1)     | 74.6 (4.7-182.1)     | 76.9 (21.4-144.9)     | 35.6 (16.4-54.7)                      |

NOTE. Data are presented as No. (%) unless otherwise noted.
H875Y mutation had PSA responses on abiraterone (Fig 2C). Using logistic regression analyses, AR LBD mutations were not significantly associated with a worse PSA response rate (\(P = .072\); Table 2). However, pathogenic AR LBD missense mutations were associated with a worse 30% or more decline in PSA (OR, 6.00; 95% CI, 1.10 to 32.76; \(P = .039\)) that remained significant in multivariable logistic regression analyses (Data Supplement).

Median time to progression was shorter in patients who had a detectable AR LBD mutation than in patients without a detectable AR LBD mutation (11.4 weeks v 28.7 weeks; \(P = .021\); Fig 2F). Using proportional hazards regression modeling, AR LBD mutations detected before therapy were associated with a shorter time to progression (HR, 2.39; 95% CI, 1.11 to 5.14; \(P = .026\)), even when controlled for ctDNA burden (\(P = .020\)) and other variables (Table 3 and Data Supplement). However, detectable AR LBD mutations were not significantly associated with worse OS (\(P = .364\); Table 3).

AR CN gain and LBD mutations were not mutually exclusive in cfDNA (Fig 1C). Two AR mutations at different allelic frequencies—T878A at 9.4% and L702H at 1.5%—were detected in one patient who experienced disease progression on abiraterone plus prednisone who also had AR CN gain (Data Supplement). Studies support the idea that the AR L702H mutation mediates an acquired response to glucocorticoids, thereby providing rationale to switch from prednisone to dexamethasone.14,20,32 In support of this notion, replacement of prednisone with dexamethasone resulted in a greater than 80% PSA decline for this patient (Data Supplement).

**TP53 and RB1**

Genetic alterations in TP53 are highly enriched in lethal prostate cancer8-11 and have recently been shown to be associated with worse PFS and OS in patients treated with abiraterone and enzalutamide.17 TP53 was highly altered in patients’ cfDNA (Figs 1C, 1D, and 3C); however, TP53

### Table 2. Response to Therapy: Univariable and Multivariable Logistic Regression Analyses (N = 62)

| Response | Patients, No. | OR       | 95% CI          | \(P\) |
|----------|---------------|----------|----------------|------|
| **Univariable** | | | | |
| Prior abiraterone or enzalutamide | 15 | 2.41 | 0.74 to 7.93 | .146 |
| PSA ≥ 20 ng/mL | 30 | 1.67 | 0.61 to 4.59 | .323 |
| Age ≥ 72 years | 32 | 1.32 | 0.48 to 3.63 | .586 |
| Visceral metastasis | 6 | 0.62 | 0.10 to 3.67 | .598 |
| ctDNA high | 27 | 3.17 | 1.11 to 9.05 | .031 |
| AR CN gain and/or LBD mutation | 34 | 1.80 | 0.65 to 5.01 | .261 |
| AR LBD mutation | 8 | 4.71 | 0.87 to 25.28 | .072 |
| AR CN gain | 32 | 2.27 | 0.81 to 6.34 | .119 |
| TP53 mutation and/or CN loss | 23 | 1.32 | 0.47 to 3.72 | .602 |
| RB1 mutation and/or CN loss | 17 | 2.35 | 0.75 to 7.35 | .141 |
| TP53 and RB1 mutation and/or CN loss | 6 | 7.73 | 0.85 to 70.65 | .070 |
| PI3K pathway defect | 15 | 8.35 | 2.09 to 34.81 | .003 |
| WNT pathway defect | 9 | 3.05 | 0.69 to 13.53 | .143 |
| BRCA1/BRCA2/ATM mutation and/or CN loss | 24 | 1.53 | 0.55 to 4.30 | .417 |
| BRCA1/BRCA2/ATM truncating mutations | 14 | 0.96 | 0.29 to 3.21 | .953 |
| **Multivariable** | | | | |
| AR LBD mutation | 8 | 4.88 | 0.85 to 28.08 | .076 |
| TP53 and RB1 mutation and/or CN loss | 6 | 5.40 | 0.56 to 52.15 | .145 |
| PI3K pathway defect | 15 | 7.09 | 1.40 to 35.94 | .018 |

**NOTE.** Significant \(P\) values are shown in bold. Multivariable analyses controlled for ctDNA high.

**Abbreviations:** AR, androgen receptor; ATM, ataxia-telangiectasia mutated gene; BRCA1/2, breast cancer gene 1/2; CN, copy number; ctDNA, circulating tumor DNA; LBD, ligand-binding domain; OR, odds ratio; PI3K, phosphoinositide 3-kinase; PSA, prostate-specific antigen; RB1, retinoblastoma-associated protein 1; TP53, tumor protein 53; WNT, wingless-type MMTV integration site.
### TABLE 3. Progression-free Survival and Overall Survival: Univariable and Multivariable Cox Proportional Hazards Regression Analyses (N = 62)

| Variable                                | Patients, No. | Progression-Free Survival | Overall Survival |
|-----------------------------------------|---------------|---------------------------|------------------|
|                                        |              | Univariable HR 95% CI P   | Univariable HR 95% CI P   |
|                                        |              | Multivariable             | Multivariable     |
| Prior abiraterone or enzalutamide       | 15            | 1.17 0.63 to 2.14 .620    | 1.51 0.71 to 3.24 .284 |
| PSA ≥ 20 ng/mL                           | 30            | 1.43 0.83 to 2.45 .193    | 1.44 0.70 to 2.95 .326 |
| Age ≥ 72 years                           | 32            | 1.04 0.60 to 1.78 .895    | 1.04 0.50 to 2.12 .925 |
| Visceral metastasis                     | 6             | 1.29 0.51 to 3.26 .595    | 2.05 0.95 to 6.63 .064 |
| ctDNA high                              | 27            | 1.76 1.03 to 3.01 .039    | 2.02 1.40 to 6.11 .004 |
| AR CN gain and/or LBD mutation          | 34            | 2.00 1.15 to 3.47 .014    | 2.95 1.36 to 6.36 .006 |
| AR LBD mutation                         | 8             | 2.39 1.11 to 5.14 .026    | 1.64 0.56 to 4.82 .364 |
| AR CN gain                              | 32            | 2.07 1.20 to 3.57 .009    | 3.26 1.52 to 7.00 .002 |
| TP53 mutation and/or CN loss            | 23            | 1.33 0.77 to 2.30 .314    | 3.19 1.53 to 6.64 .002 |
| RB1 mutation and/or CN loss             | 17            | 0.94 0.52 to 1.70 .849    | 1.47 0.68 to 3.18 .321 |
| TP53 and RB1 mutation and/or CN loss    | 6             | 1.66 0.71 to 3.91 .246    | 3.64 1.69 to 7.86 .001 |
| PI3K pathway defect                     | 15            | 1.77 0.97 to 3.22 .064    | 3.64 1.69 to 7.86 .001 |
| WNT pathway defect                      | 9             | 1.32 0.64 to 2.73 .450    | 2.92 1.28 to 6.68 .011 |
| BRCA1/BRCA2/ATM mutation and/or CN loss | 24            | 0.95 0.55 to 1.64 .855    | 3.02 0.56 to 1.54 .868 |
| BRCA1/BRCA2/ATM truncating mutations    | 14            | 0.89 0.47 to 1.68 .715    | 1.03 0.41 to 2.57 .948 |

NOTE. Significant P values are shown in bold. Multivariable analyses controlled for ctDNA high.

Abbreviations: AR, androgen receptor; ATM, ataxia-telangiectasia mutated gene; BRCA1/2, breast cancer gene 1/2; CN, copy number; ctDNA, circulating tumor DNA; HR, hazard ratio; LBD, ligand binding domain; PI3K, phosphoinositide 3-kinase; PSA, prostate-specific antigen; RB1, retinoblastoma-associated protein 1; TP53, tumor protein 53; WNT, wingless-type MMTV integration site.
defects—pathogenic mutations and/or CN loss—were not associated with PSA response ($P = .602$) or PFS ($P = .314$; Tables 2 and 3). Conversely, median OS was shorter in patients with a \( \text{TP53} \) defect compared with patients without a detectable \( \text{TP53} \) defect (68.1 weeks vs 134.9 weeks; $P = .001$; Fig 3D). Using proportional hazards regression modeling, \( \text{TP53} \) defects were associated with worse OS (HR, 3.19; 95% CI, 1.53 to 6.64; $P = .002$) that remained significant after adjusting for clinical variables (Table 3 and Data Supplement). Patients with both \( \text{TP53} \) and \( \text{RB1} \) defects had shorter median OS compared with patients with a \( \text{TP53} \) defect alone or with patients with intact \( \text{TP53} \).
Genetic Alterations in cfDNA and AR-Targeted Therapy Outcomes

**FIG 2.** Progression-free survival (PFS): Pathogenic androgen receptor (AR) ligand-binding domain (LBD) mutations are associated with a shorter time to progression. (A) Kaplan-Meier method and log-rank test were used to determine median time to progression for patients who had high versus low circulating tumor DNA (ctDNA) before therapy. (B) Waterfall plot of best prostate-specific antigen (PSA) response for all patients (N = 62) after therapy as determined by best percentage fold change in PSA. AR copy number (CN) gain and AR LBD missense mutations were determined by deep next-generation sequencing (NGS) of cell-free DNA (cfDNA) before therapy. AR LBD missense mutations were included for patients with detectable mutations. Black arrow indicates patients with prior abiraterone or enzalutamide therapy. χ² analyses for a 30% or greater and 50% or greater PSA decrease. (C) Kaplan-Meier method and log-rank test were used to determine median time to progression for patients who had a gain in circulating AR compared with patients who were AR CN neutral before therapy. The association of AR CN gain with PFS controlled for ctDNA burden using multivariable proportional hazards regression modeling. (C) Gene schematic illustrating pathogenic AR LBD mutations detected by targeted NGS of cfDNA before abiraterone and enzalutamide therapies. (E) Waterfall plot
FIG 2. (Continued). Of best PSA response for all patients (N = 62) after therapy as determined by best percentage fold change in PSA. AR LBD mutations were determined by deep NGS of cfDNA before therapy and listed below. Black arrow indicates patients with prior abiraterone or enzalutamide therapy. \( \chi^2 \) analyses for a 30% or greater and 50% or greater PSA decrease. (F) Kaplan-Meier method and log-rank test were used to determine median time to progression for patients who were positive versus negative for AR LBD mutations before therapy. The association of AR LBD mutations with PFS controlled for cfDNA burden using multivariable proportional hazards regression modeling. DBD, DNA-binding domain; NTD, N-terminal domain.
Genetic Alterations in cfDNA and AR-Targeted Therapy Outcomes

A

B

C

D

E

F

G

No. at risk

No. at risk

No. at risk

No. at risk

No. at risk

TP53

AR CN neutral

AR CN gain

Log-rank $P = .003$

Log-rank $P = .002$

Log-rank $P = .001$

Log-rank $P < .001$

Log-rank $P < .001$

Log-rank $P = .008$

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)

AR CN neutral

AR CN gain

Log-rank $P = .003$

Log-rank $P = .002$

Log-rank $P = .001$

Log-rank $P < .001$

Log-rank $P < .001$

Log-rank $P = .008$

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)

AR CN neutral

AR CN gain

Log-rank $P = .003$

Log-rank $P = .002$

Log-rank $P = .001$

Log-rank $P < .001$

Log-rank $P < .001$

Log-rank $P = .008$

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)

AR CN neutral

AR CN gain

Log-rank $P = .003$

Log-rank $P = .002$

Log-rank $P = .001$

Log-rank $P < .001$

Log-rank $P < .001$

Log-rank $P = .008$

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)

AR CN neutral

AR CN gain

Log-rank $P = .003$

Log-rank $P = .002$

Log-rank $P = .001$

Log-rank $P < .001$

Log-rank $P < .001$

Log-rank $P = .008$

OS (%)

OS (%)

OS (%)

OS (%)

OS (%)

Time (days)

Time (days)

Time (days)

Time (days)

Time (days)
on abiraterone and enzalutamide. A retrospective study reported that AR CN gain was associated with worse PFS and OS in men who were treated with enzalutamide or abiraterone for mCRPC. Similarly, AR CN gain was also reported to be associated with a worse PSA response and PFS in patients on enzalutamide. Our study also demonstrated an association of AR CN gain with PFS and OS; however, significance was lost in multivariable modeling, which is consistent with a previous report. Clearly, additional prospective studies are needed to assess the clinical strength of AR CN gain as a predictive biomarker for therapeutic response to enzalutamide and abiraterone in patients with mCRPC.

In the current study, TP53 and PI3K pathway defects were associated with worse OS. Deregulation of these pathways likely mediates resistance to androgen–AR axis therapies. Concurrent TP53 and RB1 defects are highly enriched in AR-independent neuroendocrine mCRPC compared with adenocarcinoma mCRPC. Combined TP53 and RB1 loss has been shown to promote lineage switching from an AR-dependent to an AR-independent state and consequent resistance to AR-targeted therapies. Similar to TP53, genetic alterations in PTEN are enriched in mCRPC compared with metastatic castration-sensitive prostate cancer and localized prostate cancer.

Studies suggest that PTEN loss may mediate castration resistance by downregulating AR, thereby supporting a rationale for combined inhibition of PI3K and AR in PTEN-deficient mCRPCs.

Association of pathogenic mutations in HDR genes with response to abiraterone and enzalutamide therapy is conflicting. A clinical trial in patients with mCRPC suggested that genetic alterations in HDR genes that were detected in metastatic biopsy tissue may be associated with longer PFS when on abiraterone therapy. Concordant findings were observed in a second study that supported the idea that patients with mCRPC harboring a germline BRCA1/2 or ATM mutation may also have improved outcomes to abiraterone and enzalutamide. In contrast, another study showed that truncating mutations in BRCA2 and ATM detected in cfDNA were associated with a shorter time to progression on abiraterone and enzalutamide therapies in treatment-naive patients with mCRPC. In our study, collective somatic and germline genetic alterations were also not associated with worse outcomes to enzalutamide and abiraterone. Association differences may reflect variables, such as sample size, prior treatment status, disease burden, disease heterogeneity, somatic versus germline, and single versus dual loss. Certainly, additional prospective investigation is needed to determine the clinical significance of HDR mutations as predictive markers to abiraterone and enzalutamide therapies.

In the current study, many patients had detectable alterations that could serve as potential therapeutic targets. Previous studies have shown that patients with mCRPC with either germline or somatic mutations in HDR genes achieved significant responses to olaparib and to abiraterone plus veliparib. More than one quarter of patients in our study had a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation detected before therapy or at disease progression, which suggests that these patients may benefit from therapies that target poly (ADP-ribose) polymerase or platinum-based chemotherapy. In addition, immunotherapy trials have been largely unsuccessful in men with mCRPC; however, rare responders have been reported. A seminal clinical trial demonstrated that microsatellite instable cancers caused by mismatch repair (MMR) gene deficiency were sensitive to programmed death-1 blockade, perhaps because of the formation of neoantigens resulting from increased mutational burden. Inactivation of MMR genes and elevated mutational burden have been detected in some men with aggressive prostate cancers. One patient in our study had a detectable noncanonical MMR gene mutation in his cfDNA and a correspondingly high

FIG 3. Overall survival (OS): Tumor protein p53 (TP53) and phosphoinositide 3-kinase (PI3K) pathway defects are associated with worse OS. (A) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had high versus low circulating tumor DNA (ctDNA) before therapy. (B) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had androgen receptor (AR) copy number (CN) gain before therapy. Association of AR CN gain with OS controlled for ctDNA burden using multivariable proportional hazards regression modeling. (C) Gene schematic illustrating deleterious TP53 mutations detected by deep next-generation sequencing (NGS) of cell-free DNA (cfDNA) before abiraterone and enzalutamide therapies and at disease progression while on therapy. (D) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had TP53 defects—CN loss and/or ClinVar pathogenic/likely pathogenic mutations—before therapy. Association of TP53 defects with OS controlled for cfDNA burden using multivariable proportional hazards regression modeling. (E) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had both TP53 and retinoblastoma-associated protein 1 (RB1) defects compared with patients who had TP53 defects but were RB1 intact—CN loss and/or ClinVar pathogenic/likely pathogenic mutations—before therapy. Association of dual TP53 and RB1 defects with OS controlled for cfDNA burden using multivariable proportional hazards regression modeling. (F) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had PI3K pathway defects—CN loss and/or truncating mutations in phosphatase and tensin homolog and/or CN gain of PIK3CA—before therapy. Association of PI3K defects with OS controlled for cfDNA burden using multivariable proportional hazards regression modeling. (G) Kaplan-Meier method and log-rank test were used to determine median OS for patients who had wingless-type MMTV integration site (WNT) pathway defects—CN loss and/or truncating mutations in adenomatous polyposis coli and/or CN gain and/or pathogenic missense mutations in β-catenin—before therapy. Association of WNT defects with OS controlled for cfDNA burden using multivariable proportional hazards regression modeling. P53, P53 DNA-binding domain; P53T, P53 transactivation motif; P53Tetra, P53 tetramerisation motif.
mutational burden that suggested that he may be an ideal candidate for checkpoint immunotherapy. This study supports the idea that cfDNA may be a useful analyte for directing clinical decisions in prostate cancer precision medicine.

Several limitations to our study exist. Of note, the small sample size precluded multivariable analyses that incorporated more than two variables and analyses by therapy subgroup. Consistent with other reports, patients with prior exposure to abiraterone and enzalutamide experienced worse outcomes.\(^54-59\) Statistical significance was not reached, likely because of the small overall sample size and the few patients with prior therapy. In addition, the small size precluded any definitive conclusions pertaining to the association of AR LBD mutations with outcomes. Larger prospective studies will be needed to validate our findings. Samples were obtained from two hospitals, and future prospective studies would benefit from the inclusion of a larger number of institutions. Future prospective studies would also be strengthened by radiologic confirmation of progression for every patient. An additional limitation was the variability of cfDNA input for NGS among patients. NGS protocols were adjusted on the basis of total input, but for patients with low input the lack of genetic alteration detection was considered indeterminate as opposed to negative. In addition, mutations in such genes as TP53 and ATM detected in cfDNA at low allelic frequencies may be false positives as a result of clonal hematopoiesis.\(^60\) Corresponding tissue was not available for all samples to confirm TP53 status, and future studies will examine both prostate tumor tissue and blood leukocytes for genetic alterations. A final limitation was our inability to evaluate AR splice variants, including AR-V7, because of the requirement of circulating tumor cells or whole-blood RNA. The presence of AR-V7 is certainly another established mechanism of primary and acquired resistance to next-generation hormonal therapies.\(^21-25\)

Future studies should aim to simultaneously analyze the full complement of AR aberrations, including gene mutations, amplifications, genomic structural rearrangements, and mRNA splice variants, from a single liquid biopsy.

In summary, our findings indicate cfDNA burden was highly associated with worse outcomes to enzalutamide and abiraterone. Association of AR status with outcomes was not robust and will need additional prospective validation. TP53 loss, especially in the context of concurrent RB1 defects, and PI3K pathway defects were associated with worse OS. These studies provide the rationale for larger prospective multi-institutional studies to additionally assess the clinical utility of integrating genetic alterations detected in cfDNA for the optimal management of metastatic prostate cancer.

**AFFILIATIONS**

1 Johns Hopkins School of Medicine, Baltimore, MD
2 Johns Hopkins University, Baltimore, MD

**CORRESPONDING AUTHOR**

Paula J. Hurley, PhD, The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University, CRBI 146, 1550 Orleans Ave, Baltimore, MD 21231; Twitter: @HurleyLab; @brady_urology; @HopkinsMedicine; e-mail: phurley2@jhmi.edu.

**EQUAL CONTRIBUTION**

S.T. and A.P. contributed equally to this work.

**SUPPORT**

Supported by the Department of Defense CDMRP Prostate Cancer Research Program PC130991 Grant No. W81XWH-14-1-0284 (P.J.H., B.H.P., B.J.T., A.G.), the Patrick C. Walsh Foundation (B.H.P., P.J.H.), the Prostate Cancer Foundation Young Investigator Award (E.S.A.), the Department of Defense Prostate Cancer Research Program Grant No. W81XWH-15-2-0050 (E.S.A.), National Cancer Institute Grants No. R01-CA194024 and R01-CA214494 (B.H.P.), the Breast Cancer Research Foundation (B.H.P.), and the Commonwealth Foundation (B.H.P.). B.H.P. received support from Susan G. Komen as a Komen Scholar.

**AUTHOR CONTRIBUTIONS**

Conception and design: Samantha Torquato, Emmanuel S. Antonarakis, Ben H. Park, Paula J. Hurley
Financial support: Paula J. Hurley
Administrative support: Paula J. Hurley

**Provision of study materials or patients:** Patricia Valda Toro, Michael A. Carducci, Channing J. Paller, Samuel R. Denmeade, Bruce Kessel, Mario A. Eisenberger, Emmanuel S. Antonarakis, Paula J. Hurley

**Collection and assembly of data:** Samantha Torquato, Alexa Goldstein, Patricia Valda Toro, John L. Silverstein, Justin Lee, Mary Nakazawa, Ian Waters, Daniel Shinn, Taylor Groginski, Brian W. Simons, Hamda Khan, Channing J. Paller, Samuel R. Denmeade, Bruce Kessel, Mario A. Eisenberger, Emmanuel S. Antonarakis, Paula J. Hurley

**Data analysis and interpretation:** Samantha Torquato, Aparna Pallavajjala, David Chu, Robert M. Hughes, Hamda Khan, Zhaoyong Feng, Michael A. Carducci, Channing J. Paller, Emmanuel S. Antonarakis, Bruce J. Trock, Ben H. Park, Paula J. Hurley

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or po.ascopubs.org/site/ifc.

Michael A. Carducci
Consulting or Advisory Role: Astellas Pharma, AbbVie, Genentech, Pfizer, Foundation Medicine
Research Funding: Bristol-Myers Squibb (Inst), Pfizer (Inst), AstraZeneca (Inst), Gilead Sciences (Inst), EMD Serono (Inst)
REFERENCES

1. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
2. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
3. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
4. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
5. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322, 2014
6. Baca SC, Prandi D, Lawrence MS, et al: Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228, 2015 [Erratum: Cell 162:454, 2015]
7. Grasso CS, Wu YM, Robinson DR, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243, 2012
8. Kumar A, Coleman I, Morrissey C, et al: Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369-378, 2016
9. Robinson D, Van Allen EM, Wu YM, et al: Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228, 2015 (Erratum: Cell 162:454, 2015)
10. Abida W, Armenia J, Gopalan A, et al: Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017:00029
11. Gao J, Gao J, Dugrosz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012
12. Gao J, Aksoy BA, Dugrosz U, et al: Integrative analysis of complex cancer genomes and clinical profiles using the cBioPortal. Sci Signal 6:pl1, 2013
13. Romanel A, Gasi Tandefelt D, Conteduca V, et al: Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 7:312re10, 2015
14. Azad AA, Volik SV, Wyatt AW, et al: Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 21:2315-2324, 2015
15. Goldstein A, Torro PV, Lee J, et al: Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget 8:15651-15662, 2017
16. Annals M, Vandekerkhove G, Khalaf D, et al: Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov 8:444-457, 2018
17. Salvi S, Casadio V, Conteduca V, et al: Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer 112:1717-1724, 2015
18. Conteduca V, Wetterskog D, Sharabiani MTA, et al: Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institutional correlative biomarker study. Ann Oncol 28:1508-1516, 2017
20. Wyatt AW, Azad AA, Volik SV, et al: Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2:1958-1606, 2016
21. Antonarakis ES, Lu C, Wang H, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028-1038, 2014
22. Qu F, Xie W, Nakabayashi M, et al: Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 23:726-734, 2017
23. Antonarakis ES, Lu C, Luber B, et al: Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 35:2149-2156, 2017
24. Henzler C, Li Y, Yang R, et al: Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13666, 2016
25. Shen MM, Abate-Shen C: Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 67:6535-6538, 2007
26. Jiao J, Wang S, Qiao R, et al: Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083-6091, 2007
27. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792-804, 2011
28. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
29. Hussain M, Daignault-Newton S, Twardowski PW, et al: Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. J Clin Oncol 36:991-999, 2018
30. Antonarakis ES, Changxue L, Luber B, et al: Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol 74:218-225, 2018
31. Salvi S, Casadio V, Conteuduc V, et al: Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget 7:37839-37845, 2016
32. Lalouss N, Volik SV, Awey S, et al: Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 17:10, 2016
33. Pritchard CC, Mateo J, Walsh MF, et al: Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443-453, 2016
34. Na R, Zheng SL, Han M, et al: Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71:740-747, 2017
35. Cohen JD, Li L, Wang Y, et al: Detection and localization of surgically resectable cancers with a multi-antibody blood test. Science 359:926-930, 2018
36. Leary RJ, Sausen M, Kinde I, et al: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154, 2012
37. Webb S: The cancer bloodhounds. Nat Biotechnol 34:1090-1094, 2016 [Erratum: Nat Biotechnol 35:178, 2017]
38. Wyatt AW, Annala M, Aggarwal R, et al: Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst 110:78-86, 2018
39. Beaver JA, Jelovac D, Balukrishna S, et al: Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20:2643-2650, 2014
40. Schweizer MT, Antonarakis ES: Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med 7:312fs45, 2015
41. Watson PA, Jelovac D, Volik SV, et al: Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. Ann Oncol 27:7180, 2016 (suppl 6)
42. Kwon ED, Drake CG, Scher HI, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that has progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700-712, 2014
43. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
44. Guedes LB, Antonarakis ES, Schweizer MT, et al: MSH2 loss in primary prostate cancer. Clin Cancer Res 23:6863-6874, 2017
45. Pritchard CC, Morrissey C, Kumar A, et al: Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 7:13666, 2016
46. Henzler C, Lu Y, Yang R, et al: Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13666, 2016
47. Cohen JD, Li L, Wang Y, et al: Detection and localization of surgically resectable cancers with a multi-antibody blood test. Science 359:926-930, 2018
48. Leary RJ, Sausen M, Kinde I, et al: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154, 2012
49. Wassell S: The cancer bloodhound. Nat Biotechnol 34:1090-1094, 2016 [Erratum: Nat Biotechnol 35:178, 2017]
50. Wyatt AW, Annala M, Aggarwal R, et al: Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst 110:78-86, 2018
51. Leary RJ, Sausen M, Kinde I, et al: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154, 2012
52. Wassell S: The cancer bloodhound. Nat Biotechnol 34:1090-1094, 2016 [Erratum: Nat Biotechnol 35:178, 2017]
53. Webb S: The cancer bloodhound. Nat Biotechnol 34:1090-1094, 2016 [Erratum: Nat Biotechnol 35:178, 2017]
58. Maughan BL, Luber B, Nadal R, et al: Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer. A retrospective study. Prostate 77:33-40, 2017

59. Emamekhoo H, Barata PC, Edwin NC, et al: Evaluation of response to enzalutamide consecutively after abiraterone acetate/prednisone failure in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 16:429-436, 2018

60. Hu Y, Ulrich BC, Supplee J, et al: False positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 24:4437-4443, 2018